Lung cancer drug resistance and DNA damage signaling

Peilin Zhang

The most challenging problem in cancer therapy is tumor resistance to treatment modalities, such as chemo- and radiation therapy. There are two types of resistances to DNA damage-inducing agents; first, naturally occurring resistance; and second, therapy-induced resistance. Advances in understanding the molecular mechanism that regulates the DNA damage signaling pathway makes it possible to better define the key regulatory targets involving the development of tumor resistance. In this brief review, we summarize the recent advances in DNA damage signaling, and discuss the potential targets for drug developments and better design of clinical trials for cancer patients, especially lung cancer patients.